CAS: 57310-39-1; 3-Bromo-4-Chlorotoluene

该化合物是一种芳烃卤化合物,其特点是甲基代苯环上存在溴和氯替代物,其分子结构特征是2位置的溴原子,1位置的氯原子,以及苯环4位置的甲基组.该化合物一般是无色的,根据温度和纯度,不具有黄色液体或固体的色素.该化合物以其中度挥发性为特征,在有机溶剂中可溶解,但水溶解性有限.卤素的存在有助于其再活性,使其在各种化学合成过程中有用,包括核糖替代反应.此外,2-溴-1-氯-4-甲基苯可以作为制药,农用化学品和其他有机化合物生产的中间体.在处理该物质时,应当采取安全防范措施,因为它可能因其特性而构成健康风险.

英文名称3-Bromo-4-Chlorotoluene
中文名称4-氯-3-溴甲苯
IUPAC名称2-bromo-1-chloro-4-methylbenzene
其它别名3-溴-4-氯甲苯; 4氯3溴甲苯; 2-Bromo-1-Chloro-4-Methylbenzene; 3-Bromo-4-Chlorotoluene
CAS编号57310-39-1
MFCD编号:MFCD00079710
EINECS号:611-500-9
分子式:C7H6BrCl
分子量:205.48
产品CID: 1547868
产品分类有机原料→分子砌块→芳环类化合物→苯类化合物

相似结构搜索
InChIKey: UWXPTVKKHVOZLJ-UHFFFAOYSA-N
InChI=1S/C7H6BrCl/c1-5-2-3-7(9)6(8)4-5/h2-4H,1H3…
计算化学: 氢键受体数0.0氢键供体数0.0可旋转键数0.0

MSDS等安全信息

GHS象形图
GHS符号GHS07;
注释: Exclamation mark
危险类别特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼刺激类别2
严重眼刺激类别2A
警示词Warning(警告)
危险描述H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险品标志Xi
安全声明61
危险类别码22-51/53

欧盟法规

C&L通报REACH预注册

上下游产品

合成工艺路线路线简述

2'-溴-4'-甲基乙酰苯胺置于盐酸体系中,化学反应生成 4-氯-3-溴甲苯
参考文献:Joshi; Gupta,Journal Of The Indian Chemical Society,1959,Vol. 36,P. 329,333
标题:Joshi; Gupta,Journal Of The Indian Chemical Society,1959,Vol. 36,P. 329,333

海关参考信息

2902300000-甲苯
2903919090-氯苯
2903991000-对氯甲苯
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-8178559-B2
优先权日:2004-12-30
标题:Organic compounds
发明人：BREITENSTEIN WERNER; EHARA TAKERU; EHRHARDT CLAUS; GROSCHE PHILIPP; HITOMI YUKO; IWAKI YUKI; KANAZAWA TAKANORI; KONISHI KAZUHIDE; MAIBAUM JUERGEN KLAUS; MASUYA KEIICHI; IWASAKI ATSUKO; OSTERMANN NILS; SUZUKI MASAKI; TOYAO ATSUSHI; YOKOKAWA FUMIAKI
权利人:BREITENSTEIN WERNER; EHARA TAKERU; EHRHARDT CLAUS; GROSCHE PHILIPP; HITOMI YUKO; IWAKI YUKI; KANAZAWA TAKANORI; KONISHI KAZUHIDE; MAIBAUM JUERGEN KLAUS; MASUYA KEIICHI; IWASAKI ATSUKO; OSTERMANN NILS; SUZUKI MASAKI; TOYAO ATSUSHI; YOKOKAWA FUMIAKI; NOVARTIS AG
摘要:3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.